Court Opinion

ID: 5134195
Source: CourtListenerOpinion
Date Created: 2021-12-10 23:02:37.47383+00
Date Added: 2024-06-11T08:23:42.368571
License: Public Domain

COURT OF CHANCERY
                                      OF THE
                                STATE OF DELAWARE

                                                                         417 S. State Street
JOSEPH R. SLIGHTS III                                                  Dover, Delaware 19901
 VICE CHANCELLOR                                                     Telephone: (302) 739-4397
                                                                     Facsimile: (302) 739-6179

                            Date Submitted: December 3, 2021
                            Date Decided: December 10, 2021

    Richard P. Rollo, Esquire                        R. Karl Hill, Esquire
    Angela Lam, Esquire                              Seitz Van Ogtrop & Green, P.A.
    Richards, Layton & Finger, P.A.                  222 Delaware Avenue, Suite 1500
    920 North King Street                            Wilmington, DE 19801
    Wilmington, DE 19801

         Re:    Macrophage Therapeutics, Inc. v. Goldberg
                C.A. No. 2019-0137-JRS

Dear Counsel:

         Counsel for Plaintiff, Macrophage Therapeutics, Inc. (“Macrophage”), have

submitted applications under Chancery Rule 88 (the “Applications”) in which they

seek reimbursement for attorneys’ fees and costs associated with attempts to resolve

and, later, the successful prosecution of a “Motion for Defendant Michael M.

Goldberg’s Contempt of the Status Quo Order” (the “Motion”).1 In total, counsel

for Macrophage seeks $66,796.33 as fees and expenses incurred in connection with

1
    See D.I. 60 (the Motion); D.I. 78 (Order granting the Motion).
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 2

the Motion.2 Defendant, Michael M. Goldberg, M.D. (“Dr. Goldberg”), opposes the

Applications on the ground that the fees and expenses, as requested, are excessive.3

         In the Motion, Macrophage argued that Dr. Goldberg violated the Court’s

Status Quo Order by failing to return Macrophage property he was ordered to return,

deleting electronic data he was ordered to preserve, holding himself out as having

sole authority to act for Macrophage when ordered not to do so, and making

disparaging comments about Macrophage managers when ordered not to do so.

After a hearing, the Court granted the Motion upon concluding that Dr. Goldberg

had knowingly violated the Status Quo Order as alleged. In paragraph 4 of the

Court’s Order granting the Motion, the Court stated: “Goldberg will pay

Macrophage’s fees and costs in connection with all steps necessary to cure the

2
  This amount was revised downward slightly from the amount initially sought in the
Applications following corrections made in Macrophage’s Reply in Further Support of
Rule 88 Affidavits of Richard P. Rollo, Esquire and Barry M. Kazan, Esquire. See D.I. 231.
The fees reflect work performed attempting the resolve the contempt, preparing and filing
the Motion with supporting brief, reviewing the Opposition to the Motion, preparing a reply
brief in support of the Motion, presenting the Motion at a contested hearing and then
preparing and submitting an implementing order. Id.
3
    D.I. 228.
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 3

damage that has been caused by Goldberg’s noncompliance with the [Status Quo

Order].”4

          The Order granting the Motion was entered on May 23, 2019.5 Thereafter,

the parties continued with discovery, motion practice and ultimately tried

Macrophage’s claims against Dr. Goldberg in December 2020. The Court’s post-

trial decision was issued on June 23, 2021, reflecting the Court’s verdict that

Dr. Goldberg had breached his fiduciary duty of loyalty to Macrophage and its

stockholders, but awarding only nominal damages.6 The Court entered its final

judgment to that effect on August 6, 2021.7

          Chancery Rule 88 applies to fee awards imposed as a contempt sanction.8

The rule “does not provide an independent basis for the reimbursement of a litigant’s

4
    D.I. 78 at ¶ 4.
5
    Id.
6
    D.I. 213.
7
    D.I. 222.
8
    See Dickerson v. Castle, 1992 WL 205796, at *1–2 (Del. Ch. Aug. 21, 1992).
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 4

expenses. . . .”9 Instead, it regulates the procedure by which an application for fees

is made.10 “To assess a fee’s reasonableness, case law directs a judge to consider

the factors set forth in the Delaware Lawyers’ Rules of Professional Conduct. . . .”11

The factors are: “(1) the time and labor required, the novelty and difficulty of the

questions involved, and the skill requisite to perform the legal service properly;

(2) the likelihood, if apparent to the client, that the acceptance of the particular

employment will preclude other employment by the lawyer; (3) the fee customarily

charged in the locality for similar legal services; (4) the amount involved and the

results obtained; (5) the time limitations imposed by the client or by the

circumstances; (6) the nature and length of the professional relationship with the

client; (7) the experience, reputation, and ability of the lawyer or lawyers performing

the services; and (8) whether the fee is fixed or contingent.”12

9
    Gaffin v. Teledyne, Inc., 1993 WL 271443, at * 1 (Del. Ch. July 13, 1993).
10
     Id.

 Mahani v. EDIX Media Gp., Inc., 935 A.2d 242, 245 (Del. 2007); Del. Lawyers’ R. Prof’l
11

Conduct 1.5(a).
12
     Id. at 245–46.
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 5

           When awarding expenses as a contempt sanction or for bad faith litigation

tactics, this Court takes into account the remedial nature of the award.13 “Such an

award is designed to make whole the party who was injured by the other side’s

contumely.”14 With this design in mind, the “primary emphasis is on reimbursing

the injured party. The results achieved are of secondary importance.”15

           “Determining reasonableness does not require that this Court examine

individually each time entry and disbursement.”16 Instead, the Court will consider

13
  See In re SS & C Techs., Inc. S’holders Litig., 2008 WL 3271242, at *3 n.14 (Del. Ch.
Aug. 8, 2008) (noting that because fees were awarded as a sanction, the Court did not focus
narrowly on the Rule 1.5(a) factors); Lynch v. Gonzalez, 2020 WL 5587716, at *6 (Del. Ch.
Sept. 18, 2020) (emphasizing that the court’s focus when addressing fee applications
following contempt finding should be on “reimbursing the injured party”); Arbitrium
(Cayman Islands) Handels AG v. Johnston, 1998 WL 155550, at *3 (Del. Ch. Mar. 30,
1998) (taking into account that fees were shifted because of bad faith litigation tactics when
evaluating award).
14
     Aveta, Inc. v. Bengoa, 2010 WL 3221823, at *6 (Del. Ch. Aug. 13, 2010).
15
     Id.
16
  Id. See also Weichert Co. v. Young, 2008 WL 1914309, at *2 (Del. Ch. May 1, 2008)
(“A discussion of each specific invoice item that Young contests would neither be useful
nor practicable.”); Blank Rome, LLP v. Vendel, 2003 WL 21801179, at *8–10 (Del. Ch.
Aug. 5, 2003) (rejecting alleged requirement of line-item review for contractual fee-
shifting provision); M & G Polymers USA, LLC v. Carestream Health, Inc.,
2010 WL 1611042, at *76 (Del. Super. Ct. Apr. 21, 2010) (finding no authority that
“requires this Court to engage in a line-by-line analysis of the components of an attorneys’
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 6

the Rule 1.5(a) factors as a guide and then exercise its discretion in reaching a

reasonable fee award, acknowledging that “mathematical precision” is neither

necessary nor readily achievable.17

         Dr. Goldberg’s opposition to the Applications rests on four grounds:

(1) the Motion was straightforward and should have required little by way of

attorney time to prepare and present; (2) the Motion achieved little by way of success

since, by the time the Motion was presented, Macrophage had already ceased

operations and, therefore, did not need the property and data Dr. Goldberg was

alleged to have retained in violation of the Status Quo Order; (3) the Applications

fail to disclose the billing rates of counsel; and (4) the time entries reflected on

counsels’ bills, as submitted, are too redacted to allow any meaningful review.

I address each in turn.

fee application when an award of fees is based upon the bad faith exception to the American
Rule”).
17
     See Fasciana v. Elect. Data Sys. Corp., 829 A.2d 178, 188 (Del. Ch. 2003).
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 7

         1. The Time and Labor Required, the Novelty and Difficulty of the
            Questions Involved, and the Skill Requisite to Perform the Legal
            Service Properly

         All parties to the litigation, including Dr. Goldberg, were subject to the

Status Quo Order entered by the Court.18 The Court found, and counsels’ time

entries reflect, that Dr. Goldberg began to take actions in violation of the Status Quo

Order soon after it was entered.19 Counsel for Macrophage attempted to secure

Dr. Goldberg’s compliance and then brought the Motion when those efforts failed.

While the issues involved were not particularly novel or complex, the time entries

reflect that counsel took care to present a well-supported, well-researched Motion,

as to be expected when counsel asks the Court to find an adverse party in contempt

of a Court order.20 Dr. Goldberg’s argument to the contrary is rejected.21

18
     D.I. 31.
19
   D.I. 77; D.I. 225, 226, 231 (Rule 88 Affidavits of Counsel, with attached Billing
Invoices).
20
     See Aveta, Inc., 2010 WL 3221823, at *6–7.
21
  See id. (reviewing fee request and observing that the fees were “within the range of what
a party reasonably could incur over the course of ten months pursuing an adversary
engaged in a ‘mix of open defiance, evasion and obstruction.’”). While the timeframe
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 8

          2. The Amount Involved and the Results Obtained

          As noted, when fees are incurred to expose a party’s contempt of court,

“[t]he results achieved are of secondary importance.”22 With that said, I disagree

with Dr. Goldberg that Macrophage achieved minimal results from bringing the

Motion. Dr. Goldberg took certain devices belonging to Macrophage and then

refused to return them when ordered to do so. After the successful prosecution of

the Motion, Dr. Goldberg finally complied with the Court’s Status Quo Order. That

is meaningful success. Moreover, following the Court’s Order granting the Motion,

Dr. Goldberg apparently ceased making disparaging comments regarding

Macrophage’s management to Macrophage’s business partners and stopped holding

himself out as the voice of Macrophage. That, too, is success. Finally, the Court’s

purpose in reviewing the Applications is not to “relitigate [the Motion] in hindsight

or place substantial weight on motion-by-motion outcomes in view of the ‘remedial

nature’ of the award that put[s] primary emphasis on reimbursing the injured

involved here is clearly less than ten months, the fees requested (and awarded) in Aveta
exceeded $700,000. Id.
22
     Id. at *6.
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 9

party.”23 Macrophage was “injured by Dr. Goldberg’s contumely.”24 It is entitled

to be made whole.25

         3. The Billing Rates of Counsel

         Dr. Goldberg correctly observed in his opposition that counsel for

Macrophage did not identify the billing rates for individual timekeepers. That

omission was corrected in supplemental declarations from counsel attached to

Macrophage’s reply.26 The billing rates are reasonable and consistent with those

“customarily charged in the locality for similar legal services.”27

         4. Redactions

         Dr. Goldberg maintains that the billing records are too heavily redacted to

allow for meaningful review. I disagree. To be sure, the records are heavily

23
     Lynch, 2020 WL 5587716, at *6.
24
     Aveta, Inc., 2010 WL 3221823, at *6.
25
  See id. (holding that fees incurred in prosecuting a motion for contempt “must be borne
by [the contemnor] whose conduct necessitated the services that fee represents.”).
26
     D.I. 231, Ex. C, Ex. 3.
27
     Del. Lawyers’ R. Prof’l Conduct 1.5(a).
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 10

redacted. But the redactions are of time entries describing work unrelated to the

Motion.28 The unredacted time entries adequately describe the work performed to

mitigate the effects of Dr. Goldberg’s contempt and to prepare and prosecute the

Motion.          And, with the clarifications provided in Macrophage’s reply, which

Dr. Goldberg was given an opportunity to address,29 I am satisfied the amount

requested is reasonable under the circumstances.30

                                          *****

         Based on the foregoing, Macrophage’s Applications for reimbursement of

attorney’s fees are GRANTED. Dr. Goldberg shall reimburse Macrophage for fees

28
     D.I. 231.
29
   D.I. 233, 234. I note here that Dr. Goldberg’s refrain is that the fees requested are
excessive. He does not, however, proffer what he believes would be a reasonable fee
request for the work performed, nor does he offer evidence of the fees he incurred in
connection with defending the allegations of contempt. Cf. Danenberg v. Fitracks, Inc.,
58 A.3d 991, 1001 (Del. Ch. 2012) (observing that party challenging reasonableness of fee
request in an advancement action was ordered to submit its own bills).
30
   The reply reveals corrections to time entries attached to counsel’s initial Declaration,
see D.I. 225, Ex. A, that reflected excessive time spent on email correspondence and cite
checking the Motion. D.I. 233, Ex. C. The corrections reveal that the time entered
combined work on the Motion with work unrelated to the Motion. The corrected
submission unbundled that time and seeks reimbursement only for time spent working on
the Motion.
Macrophage Therapeutics, Inc. v. Goldberg
C.A. No. 2019-0137-JRS
December 10, 2021
Page 11

and costs incurred in connection with the Motion in the amount of $66,796.33 within

thirty (30) days of the date of this opinion and order.

      IT IS SO ORDERED.

                                        Very truly yours,

                                        /s/ Joseph R. Slights III